STVN — Stevanato Group S.p.A. stock price, charts and financials

QT50Stevanato Group S.p.A.

Stevanato Group S.p.A. (NYSE: STVN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
20.42
+0.15+0.74%
OverviewShort InterestFilings
STVNQT50Stevanato Group S.p.A.·NYSE
20.42+0.74%
News
Up 0.7% — Stevanato Group Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MMSI+1.34%$90.23TFX-0.38%$134.47BLCO+0.54%$16.87ICUI+0.26%$185.04NVST-0.09%$28.13ATR-0.97%$134.11AVTR+0.59%$13.67RGEN-0.71%$162.74
Snapshot
Index-P/E34.38EPS (ttm)0.59Insider Own0.24%Shs Outstand273.01MPerf Week2.12%
Market Cap5.53BForward P/E23.91EPS next Y0.85Insider Trans-0.90%Shs Float273.01MPerf Month2.63%
Enterprise Value5.92BPEG4.04EPS next Q-Inst Own-Short Float0.35%Perf Quarter12.42%
Income162.72MP/S3.99EPS this Y20.13%Inst Trans-Short Ratio2.36Perf Half Y43.25%
Sales1.39BP/B3.13EPS next Y19.63%ROA5.46%Short Interest966.43KPerf YTD0.75%
Book/sh-P/C18.41EPS next 5Y19.29%ROE9.63%52W High28.21 -27.61%Perf Year-15.72%
Cash/sh-P/FCF-EPS past 3/5Y-0.27% 11.60%ROIC6.77%52W Low12.99 57.25%Perf 3Y-36.99%
Dividend Est.0.06 (0.30%)EV/EBITDA17.42Sales past 3/5Y7.51% 11.22%Gross Margin29.01%Volatility4.35% 4.18%Perf 5Y0.40%
Dividend TTM0.06 (0.30%)EV/Sales4.27EPS Y/Y TTM26.82%Oper. Margin16.57%ATR (14)0.85Perf 10Y-
Dividend Ex-DateJun 11, 2026Quick Ratio1.11Sales Y/Y TTM16.50%Profit Margin11.75%RSI (14)57.66Recom2.38
Dividend Gr. 3/5Y6.61% -Current Ratio1.63EPS Q/Q18.18%SMA202.43%Beta0.70Target Price24.75
Payout0.04%Debt/Eq0.29Sales Q/Q18.52%SMA507.90%Rel Volume0.85Prev Close20.27
Employees6,010LT Debt/Eq0.23EarningsNov 05SMA2008.68%Avg Volume362.37KPrice20.42
IPO DateJul 16, 2021Option/ShortYes / YesEPS/Sales Surpr.7.11% 0.11%Net Debt/EBITDA1.14Volume306,404Change0.74%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-05-26ReiteratedKeybancOverweight$32
Feb-10-26ReiteratedJefferiesHold$23 → $18
Aug-07-24ReiteratedCitigroupBuy$28
Nov-01-23DowngradeJefferiesBuy → Hold
Sep-26-23ReiteratedStephens$33
Aug-24-23DowngradeMorgan StanleyOverweight → Equal Weight
Jan-06-23ReiteratedMorgan StanleyOverweight$22
Apr-25-22ReiteratedWells FargoOverweight$19
Latest News
Aug-09-26
Aug-09-2604:04AM
Stevanato Group Q2 Earnings Call Highlightsmarketbeat.com
Aug-05-26
Aug-05-2601:46PM
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"zacks.com
Aug-04-26
Aug-04-2603:20PM
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcriptseekingalpha.com
08:51AM
Stevanato Group (STVN) Q2 Earnings Top Estimateszacks.com
06:30AM
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026businesswire.com
Jul-30-26
Jul-30-2606:38AM
Stevanato Group Says Liraglutide-Based Combination Products Incorporating Its Proprietary Alina Pen Injector Platform Receives Marketing Authorizations In EuropeBenzinga
06:30AM
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countriesbusinesswire.com
Jul-21-26
Jul-21-2606:30AM
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026businesswire.com
Jun-16-26
Jun-16-2609:56PM
TD Cowen Initiates Coverage of Stevanato Group S.p.A. (STVN) with Buy RecommendationFintel
01:02PM
TD Cowen Initiates Coverage On Stevanato Group with Buy Rating, Announces Price Target of $25Benzinga
Jun-11-26
Jun-11-2602:54AM
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling UpsideSeekingAlpha
Company

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue1,3911,2851,194—————
Cost of Goods Sold Incl. D&A987913867—————
Gross Profit403373327—————
Selling, General and Administrative Excl. Other147139128—————
Research and Development302834—————
Other Operating Expense-4-1-9—————
Operating Income231207174—————
Interest Expense10257—————
Unusual Expense
————————
Non-Operating Income (Expense)3237—————
Net Income Before Taxes223205173—————
Income Taxes605346—————
Consolidated Net Income164151127—————
Net Income From Continuing Operations164151127—————
Net Income164151127—————
EPS (Recurring)0.590.550.47—————
EPS (Basic, Before Extraordinaries)0.590.550.47—————
EPS (Diluted)0.590.550.47—————
EBITDA342326268—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio34.6136.4046.84—————
Price To Sales Ratio4.014.274.98—————
Gross Margin28.9729.0327.39—————
Operating Margin16.6116.1114.57—————
Net Margin11.7911.7510.64—————
Shares Outstanding273273273—————
Market Capitalization5,5755,4935,949—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$30.13$25.41$20.69$15.97$11.25● Close Price0.00K25.52K51.03K76.55K102.06KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Balachandran MadhavanDirectorJun 15 '26Sale17.091,49325,51569,458Jun 26
MOREL DONALD E JRDirectorJun 15 '26Sale17.091,49325,51537,424Jun 26
FEDERICI WILLIAM JDirectorJun 15 '26Sale17.091,49325,51526,991Jun 26
Flynn KarenDirectorJun 15 '26Sale17.091,49325,5155,757Jun 26
Dal Lago MarcoChief Financial OfficerJun 12 '26Option Exercise0.0015,994085,353Jun 26
Stocchi MauroSee RemarksJun 09 '26Option Exercise0.0013,1720413,629Jun 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.